L&C Bio Co., Ltd. logo

L&C Bio Co., Ltd. (290650)

Market Open
11 Aug, 06:30
KRX SM KRX SM
65,000. 00
+400
+0.6192%
1.49T Market Cap
- P/E Ratio
200% Div Yield
8,409 Volume
- Eps
64,600
Previous Close
Add Transaction
Day Range
63,400 65,200
Year Range
29,100 125,000
Want to track 290650 and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!

Summary

290650 trading today higher at ₩65,000, an increase of 0.6192% from yesterday's close, completing a monthly decrease of -27.3743% or -₩24,500. Over the past 12 months, 290650 stock gained 7.7944%.
290650 pays dividends to its shareholders, with the most recent payment made on Apr 01, 2026. The next estimated payment will be in In 7 months on Apr 01, 2027 for a total of ₩50.
The last earnings report, released on Feb 15, 2024, exceeded the consensus estimates by 0%. On average, the company has surpassed earnings expectations by 0%, based on the last three reports.
L&C Bio Co., Ltd. has completed 1 stock splits, with the recent split occurring on Oct 12, 2020.
The company's stock is traded on one exchange.

290650 Chart

People also search for

Samsung Biologics Co., Ltd.
1,588,000
+1.211%
Celltrion Inc.
204,500
+1.7413%
ALTEOGEN Inc.
340,500
-2.1552%
Sk Biopharmaceuticals Co., Ltd.
90,600
+2.1421%
ABL Bio Inc.
92,300
-1.3889%

L&C Bio Co., Ltd. (290650) FAQ

What is the stock price today?

The current price is ₩65,000.00.

On which exchange is it traded?

L&C Bio Co., Ltd. is listed on KRX SM.

What is its stock symbol?

The ticker symbol is 290650.

Does it pay dividends? What is the current yield?

Yes, It pays dividends and the current yield is 200%.

What is its market cap?

As of today, the market cap is 1.49T.

Has L&C Bio Co., Ltd. ever had a stock split?

L&C Bio Co., Ltd. had 1 splits and the recent split was on Oct 12, 2020.

L&C Bio Co., Ltd. Profile

Biotechnology Industry
Healthcare Sector
- CEO
KRX SM Exchange
KR7290650001 ISIN
KR Country
128 Employees
29 Dec 2025 Last Dividend
12 Oct 2020 Last Split
- IPO Date

Overview

L&C Bio Co., Ltd is engaged in the pioneering field of tissue regeneration medicine, focusing on the research and development of innovative solutions aimed at promoting healing and improving quality of life. Established in 2011, the company has quickly positioned itself as a leader in its sector. Headquartered in Seongnam-si, South Korea, L&C Bio leverages cutting-edge technology and scientific research to develop products that span across various applications, including human tissue engineering, medical devices, and cosmetic products. Its dedication to advancing tissue regeneration medicine reflects its commitment to addressing some of the most challenging medical issues faced today.

Products and Services

  • Human Tissue Products

At the core of L&C Bio’s product lineup are human tissue products designed for medical applications requiring tissue regeneration and repair. These products are developed with the aim of facilitating faster recovery and better outcomes for patients undergoing surgical procedures or those in need of tissue regeneration due to injury or disease.

  • Medical Device Products

L&C Bio also ventures into the creation of medical devices that support or enhance the process of tissue healing and regeneration. Drawing from its research in tissue engineering, the company designs devices that can be used in various medical settings, contributing to the advancement of regenerative medicine practices.

  • Cosmetic Products

Beyond its medical applications, L&C Bio has expanded its expertise into the development of cosmetic products. These products leverage the company’s background in tissue regeneration to offer solutions aimed at enhancing skin health and appearance, catering to a broader market with a focus on aesthetics and personal care.

Contact Information

Address: Suntechcity
Phone: 82 2 541 8577